Developer of candidate drugs. The company develops drugs in the sectors of immune-modulator therapeutics inhibiting graft rejection, anti-viral applications of the zinc finger ejector in the field of haemorrhagic fever and oncoviruses, anti-HIV drugs, and low molecular weight azo-compounds.
Missing: H-Phar's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: H-Phar's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing H-Phar
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
H-Phar is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
H-Phar Frequently Asked Questions (FAQ)
When was H-Phar founded?
H-Phar was founded in 2002.
Where is H-Phar's headquarters?
H-Phar's headquarters is located at Chaussée de Bruxelles 141, Jumet.
What is H-Phar's latest funding round?
H-Phar's latest funding round is Series B.
How much did H-Phar raise?
H-Phar raised a total of $9.25M.
Who are the investors of H-Phar?
Investors of H-Phar include Sambrinvest.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.